bis((2R)-N-[(2S,5R)-5-[[(1S,5R)-6-bicyclo[3.1.0]hexanyl]methyl]-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-methyl-5-morpholin-4-yl-4-oxopentanamide);(2R)-N-[(1R,2S,5R)-5-(cyclohexen-1-ylmethyl)-1-hydroxy-6-[(2R)-2-methyloxiran-2-yl]-1-(4-methylsulfonylphenyl)-3,6-dioxohexan-2-yl]-2-methyl-5-morpholin-4-yl-4-oxopentanamide;(2S)-N-[(1R,2S,5R)-5-(cyclopenten-1-ylmethyl)-1-hydroxy-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-(hydroxymethyl)-5-morpholin-4-yl-4-oxopentanamide;(2R)-N-[(1R,2S,5R)-5-(cyclopenten-1-ylmethyl)-1-hydroxy-6-[(2R)-2-methyloxiran-2-yl]-1-(4-methylsulfonylphenyl)-3,6-dioxohexan-2-yl]-2-methyl-5-morpholin-4-yl-4-oxopentanamide;(2R)-N-[(2S,5R)-5-(cyclopenten-1-ylmethyl)-1-(2-methoxy-4-pyridinyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-methyl-5-morpholin-4-yl-4-oxopentanamide

C194H269N13O48S2 — CID 159906607

About bis((2R)-N-[(2S,5R)-5-[[(1S,5R)-6-bicyclo[3.1.0]hexanyl]methyl]-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-methyl-5-morpholin-4-yl-4-oxopentanamide);(2R)-N-[(1R,2S,5R)-5-(cyclohexen-1-ylmethyl)-1-hydroxy-6-[(2R)-2-methyloxiran-2-yl]-1-(4-methylsulfonylphenyl)-3,6-dioxohexan-2-yl]-2-methyl-5-morpholin-4-yl-4-oxopentanamide;(2S)-N-[(1R,2S,5R)-5-(cyclopenten-1-ylmethyl)-1-hydroxy-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-(hydroxymethyl)-5-morpholin-4-yl-4-oxopentanamide;(2R)-N-[(1R,2S,5R)-5-(cyclopenten-1-ylmethyl)-1-hydroxy-6-[(2R)-2-methyloxiran-2-yl]-1-(4-methylsulfonylphenyl)-3,6-dioxohexan-2-yl]-2-methyl-5-morpholin-4-yl-4-oxopentanamide;(2R)-N-[(2S,5R)-5-(cyclopenten-1-ylmethyl)-1-(2-methoxy-4-pyridinyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-methyl-5-morpholin-4-yl-4-oxopentanamide

bis((2R)-N-[(2S,5R)-5-[[(1S,5R)-6-bicyclo[3.1.0]hexanyl]methyl]-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-methyl-5-morpholin-4-yl-4-oxopentanamide);(2R)-N-[(1R,2S,5R)-5-(cyclohexen-1-ylmethyl)-1-hydroxy-6-[(2R)-2-methyloxiran-2-yl]-1-(4-methylsulfonylphenyl)-3,6-dioxohexan-2-yl]-2-methyl-5-morpholin-4-yl-4-oxopentanamide;(2S)-N-[(1R,2S,5R)-5-(cyclopenten-1-ylmethyl)-1-hydroxy-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-(hydroxymethyl)-5-morpholin-4-yl-4-oxopentanamide;(2R)-N-[(1R,2S,5R)-5-(cyclopenten-1-ylmethyl)-1-hydroxy-6-[(2R)-2-methyloxiran-2-yl]-1-(4-methylsulfonylphenyl)-3,6-dioxohexan-2-yl]-2-methyl-5-morpholin-4-yl-4-oxopentanamide;(2R)-N-[(2S,5R)-5-(cyclopenten-1-ylmethyl)-1-(2-methoxy-4-pyridinyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-methyl-5-morpholin-4-yl-4-oxopentanamide (PubChem CID 159906607) has the molecular formula C194H269N13O48S2 and a molecular weight of 3615.46 g/mol. Its IUPAC name is bis((2R)-N-[(2S,5R)-5-[[(1S,5R)-6-bicyclo[3.1.0]hexanyl]methyl]-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-methyl-5-morpholin-4-yl-4-oxopentanamide);(2R)-N-[(1R,2S,5R)-5-(cyclohexen-1-ylmethyl)-1-hydroxy-6-[(2R)-2-methyloxiran-2-yl]-1-(4-methylsulfonylphenyl)-3,6-dioxohexan-2-yl]-2-methyl-5-morpholin-4-yl-4-oxopentanamide;(2S)-N-[(1R,2S,5R)-5-(cyclopenten-1-ylmethyl)-1-hydroxy-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-(hydroxymethyl)-5-morpholin-4-yl-4-oxopentanamide;(2R)-N-[(1R,2S,5R)-5-(cyclopenten-1-ylmethyl)-1-hydroxy-6-[(2R)-2-methyloxiran-2-yl]-1-(4-methylsulfonylphenyl)-3,6-dioxohexan-2-yl]-2-methyl-5-morpholin-4-yl-4-oxopentanamide;(2R)-N-[(2S,5R)-5-(cyclopenten-1-ylmethyl)-1-(2-methoxy-4-pyridinyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-methyl-5-morpholin-4-yl-4-oxopentanamide.

Molecular Properties

• Compound Name: bis((2R)-N-[(2S,5R)-5-[[(1S,5R)-6-bicyclo[3.1.0]hexanyl]methyl]-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-methyl-5-morpholin-4-yl-4-oxopentanamide);(2R)-N-[(1R,2S,5R)-5-(cyclohexen-1-ylmethyl)-1-hydroxy-6-[(2R)-2-methyloxiran-2-yl]-1-(4-methylsulfonylphenyl)-3,6-dioxohexan-2-yl]-2-methyl-5-morpholin-4-yl-4-oxopentanamide;(2S)-N-[(1R,2S,5R)-5-(cyclopenten-1-ylmethyl)-1-hydroxy-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-(hydroxymethyl)-5-morpholin-4-yl-4-oxopentanamide;(2R)-N-[(1R,2S,5R)-5-(cyclopenten-1-ylmethyl)-1-hydroxy-6-[(2R)-2-methyloxiran-2-yl]-1-(4-methylsulfonylphenyl)-3,6-dioxohexan-2-yl]-2-methyl-5-morpholin-4-yl-4-oxopentanamide;(2R)-N-[(2S,5R)-5-(cyclopenten-1-ylmethyl)-1-(2-methoxy-4-pyridinyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-methyl-5-morpholin-4-yl-4-oxopentanamide
• PubChem CID: 159906607
• Molecular Formula: C194H269N13O48S2
• Molecular Weight: 3615.46 g/mol
• Exact Mass: 3612.84
• IUPAC Name: bis((2R)-N-[(2S,5R)-5-[[(1S,5R)-6-bicyclo[3.1.0]hexanyl]methyl]-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-methyl-5-morpholin-4-yl-4-oxopentanamide);(2R)-N-[(1R,2S,5R)-5-(cyclohexen-1-ylmethyl)-1-hydroxy-6-[(2R)-2-methyloxiran-2-yl]-1-(4-methylsulfonylphenyl)-3,6-dioxohexan-2-yl]-2-methyl-5-morpholin-4-yl-4-oxopentanamide;(2S)-N-[(1R,2S,5R)-5-(cyclopenten-1-ylmethyl)-1-hydroxy-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-(hydroxymethyl)-5-morpholin-4-yl-4-oxopentanamide;(2R)-N-[(1R,2S,5R)-5-(cyclopenten-1-ylmethyl)-1-hydroxy-6-[(2R)-2-methyloxiran-2-yl]-1-(4-methylsulfonylphenyl)-3,6-dioxohexan-2-yl]-2-methyl-5-morpholin-4-yl-4-oxopentanamide;(2R)-N-[(2S,5R)-5-(cyclopenten-1-ylmethyl)-1-(2-methoxy-4-pyridinyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-methyl-5-morpholin-4-yl-4-oxopentanamide
• SMILES: COc1cc(C[C@H](NC(=O)[C@H](C)CC(=O)CN2CCOCC2)C(=O)C[C@@H](CC2=CCCC2)C(=O)[C@@]2(C)CO2)ccn1.COc1ccc(C[C@H](NC(=O)[C@H](C)CC(=O)CN2CCOCC2)C(=O)C[C@@H](CC2[C@H]3CCC[C@@H]23)C(=O)[C@@]2(C)CO2)cc1.COc1ccc(C[C@H](NC(=O)[C@H](C)CC(=O)CN2CCOCC2)C(=O)C[C@@H](CC2[C@H]3CCC[C@@H]23)C(=O)[C@@]2(C)CO2)cc1.COc1ccc([C@@H](O)[C@H](NC(=O)C(CO)CC(=O)CN2CCOCC2)C(=O)C[C@@H](CC2=CCCC2)C(=O)[C@@]2(C)CO2)cc1.C[C@H](CC(=O)CN1CCOCC1)C(=O)N[C@H](C(=O)C[C@@H](CC1=CCCC1)C(=O)[C@@]1(C)CO1)[C@H](O)c1ccc(S(C)(=O)=O)cc1.C[C@H](CC(=O)CN1CCOCC1)C(=O)N[C@H](C(=O)C[C@@H](CC1=CCCCC1)C(=O)[C@@]1(C)CO1)[C@H](O)c1ccc(S(C)(=O)=O)cc1
• InChI: InChI=1S/C33H46N2O9S.2C33H46N2O7.C32H44N2O9S.C32H44N2O9.C31H43N3O7/c1-22(17-26(36)20-35-13-15-43-16-14-35)32(40)34-29(30(38)24-9-11-27(12-10-24)45(3,41)42)28(37)19-25(31(39)33(2)21-44-33)18-23-7-5-4-6-8-23;2*1-21(15-24(36)19-35-11-13-41-14-12-35)32(39)34-29(16-22-7-9-25(40-3)10-8-22)30(37)18-23(31(38)33(2)20-42-33)17-28-26-5-4-6-27(26)28;1-21(16-25(35)19-34-12-14-42-15-13-34)31(39)33-28(29(37)23-8-10-26(11-9-23)44(3,40)41)27(36)18-24(17-22-6-4-5-7-22)30(38)32(2)20-43-32;1-32(20-43-32)30(39)23(15-21-5-3-4-6-21)17-27(37)28(29(38)22-7-9-26(41-2)10-8-22)33-31(40)24(19-35)16-25(36)18-34-11-13-42-14-12-34;1-21(14-25(35)19-34-10-12-40-13-11-34)30(38)33-26(16-23-8-9-32-28(17-23)39-3)27(36)18-24(15-22-6-4-5-7-22)29(37)31(2)20-41-31/h7,9-12,22,25,29-30,38H,4-6,8,13-21H2,1-3H3,(H,34,40);2*7-10,21,23,26-29H,4-6,11-20H2,1-3H3,(H,34,39);6,8-11,21,24,28-29,37H,4-5,7,12-20H2,1-3H3,(H,33,39);5,7-10,23-24,28-29,35,38H,3-4,6,11-20H2,1-2H3,(H,33,40);6,8-9,17,21,24,26H,4-5,7,10-16,18-20H2,1-3H3,(H,33,38)/t22-,25-,29-,30-,33-;2*21-,23-,26-,27+,28?,29+,33-;21-,24-,28-,29-,32-;23-,24?,28-,29-,32-;21-,24-,26+,31-/m111111/s1
• InChIKey: NWQRXFSZRGOKBC-BGOANBRWSA-N
• XLogP: 14.39
• TPSA: 830.87 Ų
• H-Bond Donors: 10
• H-Bond Acceptors: 55
• Rotatable Bonds: 97
• Heavy Atoms: 257
• Complexity: —

Lipinski Rule of Five

4 violations

Rule	Value
MW ≤ 500	3615.46
LogP ≤ 5	14.39
H-Bond Donors ≤ 5	10
H-Bond Acceptors ≤ 10	55

Frequently Asked Questions

What is the IUPAC name of bis((2R)-N-[(2S,5R)-5-[[(1S,5R)-6-bicyclo[3.1.0]hexanyl]methyl]-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-methyl-5-morpholin-4-yl-4-oxopentanamide);(2R)-N-[(1R,2S,5R)-5-(cyclohexen-1-ylmethyl)-1-hydroxy-6-[(2R)-2-methyloxiran-2-yl]-1-(4-methylsulfonylphenyl)-3,6-dioxohexan-2-yl]-2-methyl-5-morpholin-4-yl-4-oxopentanamide;(2S)-N-[(1R,2S,5R)-5-(cyclopenten-1-ylmethyl)-1-hydroxy-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-(hydroxymethyl)-5-morpholin-4-yl-4-oxopentanamide;(2R)-N-[(1R,2S,5R)-5-(cyclopenten-1-ylmethyl)-1-hydroxy-6-[(2R)-2-methyloxiran-2-yl]-1-(4-methylsulfonylphenyl)-3,6-dioxohexan-2-yl]-2-methyl-5-morpholin-4-yl-4-oxopentanamide;(2R)-N-[(2S,5R)-5-(cyclopenten-1-ylmethyl)-1-(2-methoxy-4-pyridinyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-methyl-5-morpholin-4-yl-4-oxopentanamide?

The IUPAC name of bis((2R)-N-[(2S,5R)-5-[[(1S,5R)-6-bicyclo[3.1.0]hexanyl]methyl]-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-methyl-5-morpholin-4-yl-4-oxopentanamide);(2R)-N-[(1R,2S,5R)-5-(cyclohexen-1-ylmethyl)-1-hydroxy-6-[(2R)-2-methyloxiran-2-yl]-1-(4-methylsulfonylphenyl)-3,6-dioxohexan-2-yl]-2-methyl-5-morpholin-4-yl-4-oxopentanamide;(2S)-N-[(1R,2S,5R)-5-(cyclopenten-1-ylmethyl)-1-hydroxy-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-(hydroxymethyl)-5-morpholin-4-yl-4-oxopentanamide;(2R)-N-[(1R,2S,5R)-5-(cyclopenten-1-ylmethyl)-1-hydroxy-6-[(2R)-2-methyloxiran-2-yl]-1-(4-methylsulfonylphenyl)-3,6-dioxohexan-2-yl]-2-methyl-5-morpholin-4-yl-4-oxopentanamide;(2R)-N-[(2S,5R)-5-(cyclopenten-1-ylmethyl)-1-(2-methoxy-4-pyridinyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-methyl-5-morpholin-4-yl-4-oxopentanamide (CID 159906607) is bis((2R)-N-[(2S,5R)-5-[[(1S,5R)-6-bicyclo[3.1.0]hexanyl]methyl]-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-methyl-5-morpholin-4-yl-4-oxopentanamide);(2R)-N-[(1R,2S,5R)-5-(cyclohexen-1-ylmethyl)-1-hydroxy-6-[(2R)-2-methyloxiran-2-yl]-1-(4-methylsulfonylphenyl)-3,6-dioxohexan-2-yl]-2-methyl-5-morpholin-4-yl-4-oxopentanamide;(2S)-N-[(1R,2S,5R)-5-(cyclopenten-1-ylmethyl)-1-hydroxy-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-(hydroxymethyl)-5-morpholin-4-yl-4-oxopentanamide;(2R)-N-[(1R,2S,5R)-5-(cyclopenten-1-ylmethyl)-1-hydroxy-6-[(2R)-2-methyloxiran-2-yl]-1-(4-methylsulfonylphenyl)-3,6-dioxohexan-2-yl]-2-methyl-5-morpholin-4-yl-4-oxopentanamide;(2R)-N-[(2S,5R)-5-(cyclopenten-1-ylmethyl)-1-(2-methoxy-4-pyridinyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-methyl-5-morpholin-4-yl-4-oxopentanamide.

What is the SMILES notation for bis((2R)-N-[(2S,5R)-5-[[(1S,5R)-6-bicyclo[3.1.0]hexanyl]methyl]-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-methyl-5-morpholin-4-yl-4-oxopentanamide);(2R)-N-[(1R,2S,5R)-5-(cyclohexen-1-ylmethyl)-1-hydroxy-6-[(2R)-2-methyloxiran-2-yl]-1-(4-methylsulfonylphenyl)-3,6-dioxohexan-2-yl]-2-methyl-5-morpholin-4-yl-4-oxopentanamide;(2S)-N-[(1R,2S,5R)-5-(cyclopenten-1-ylmethyl)-1-hydroxy-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-(hydroxymethyl)-5-morpholin-4-yl-4-oxopentanamide;(2R)-N-[(1R,2S,5R)-5-(cyclopenten-1-ylmethyl)-1-hydroxy-6-[(2R)-2-methyloxiran-2-yl]-1-(4-methylsulfonylphenyl)-3,6-dioxohexan-2-yl]-2-methyl-5-morpholin-4-yl-4-oxopentanamide;(2R)-N-[(2S,5R)-5-(cyclopenten-1-ylmethyl)-1-(2-methoxy-4-pyridinyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-methyl-5-morpholin-4-yl-4-oxopentanamide?

The canonical SMILES for bis((2R)-N-[(2S,5R)-5-[[(1S,5R)-6-bicyclo[3.1.0]hexanyl]methyl]-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-methyl-5-morpholin-4-yl-4-oxopentanamide);(2R)-N-[(1R,2S,5R)-5-(cyclohexen-1-ylmethyl)-1-hydroxy-6-[(2R)-2-methyloxiran-2-yl]-1-(4-methylsulfonylphenyl)-3,6-dioxohexan-2-yl]-2-methyl-5-morpholin-4-yl-4-oxopentanamide;(2S)-N-[(1R,2S,5R)-5-(cyclopenten-1-ylmethyl)-1-hydroxy-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-(hydroxymethyl)-5-morpholin-4-yl-4-oxopentanamide;(2R)-N-[(1R,2S,5R)-5-(cyclopenten-1-ylmethyl)-1-hydroxy-6-[(2R)-2-methyloxiran-2-yl]-1-(4-methylsulfonylphenyl)-3,6-dioxohexan-2-yl]-2-methyl-5-morpholin-4-yl-4-oxopentanamide;(2R)-N-[(2S,5R)-5-(cyclopenten-1-ylmethyl)-1-(2-methoxy-4-pyridinyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-methyl-5-morpholin-4-yl-4-oxopentanamide is COc1cc(C[C@H](NC(=O)[C@H](C)CC(=O)CN2CCOCC2)C(=O)C[C@@H](CC2=CCCC2)C(=O)[C@@]2(C)CO2)ccn1.COc1ccc(C[C@H](NC(=O)[C@H](C)CC(=O)CN2CCOCC2)C(=O)C[C@@H](CC2[C@H]3CCC[C@@H]23)C(=O)[C@@]2(C)CO2)cc1.COc1ccc(C[C@H](NC(=O)[C@H](C)CC(=O)CN2CCOCC2)C(=O)C[C@@H](CC2[C@H]3CCC[C@@H]23)C(=O)[C@@]2(C)CO2)cc1.COc1ccc([C@@H](O)[C@H](NC(=O)C(CO)CC(=O)CN2CCOCC2)C(=O)C[C@@H](CC2=CCCC2)C(=O)[C@@]2(C)CO2)cc1.C[C@H](CC(=O)CN1CCOCC1)C(=O)N[C@H](C(=O)C[C@@H](CC1=CCCC1)C(=O)[C@@]1(C)CO1)[C@H](O)c1ccc(S(C)(=O)=O)cc1.C[C@H](CC(=O)CN1CCOCC1)C(=O)N[C@H](C(=O)C[C@@H](CC1=CCCCC1)C(=O)[C@@]1(C)CO1)[C@H](O)c1ccc(S(C)(=O)=O)cc1.

What is the InChIKey of bis((2R)-N-[(2S,5R)-5-[[(1S,5R)-6-bicyclo[3.1.0]hexanyl]methyl]-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-methyl-5-morpholin-4-yl-4-oxopentanamide);(2R)-N-[(1R,2S,5R)-5-(cyclohexen-1-ylmethyl)-1-hydroxy-6-[(2R)-2-methyloxiran-2-yl]-1-(4-methylsulfonylphenyl)-3,6-dioxohexan-2-yl]-2-methyl-5-morpholin-4-yl-4-oxopentanamide;(2S)-N-[(1R,2S,5R)-5-(cyclopenten-1-ylmethyl)-1-hydroxy-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-(hydroxymethyl)-5-morpholin-4-yl-4-oxopentanamide;(2R)-N-[(1R,2S,5R)-5-(cyclopenten-1-ylmethyl)-1-hydroxy-6-[(2R)-2-methyloxiran-2-yl]-1-(4-methylsulfonylphenyl)-3,6-dioxohexan-2-yl]-2-methyl-5-morpholin-4-yl-4-oxopentanamide;(2R)-N-[(2S,5R)-5-(cyclopenten-1-ylmethyl)-1-(2-methoxy-4-pyridinyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-methyl-5-morpholin-4-yl-4-oxopentanamide?

The InChIKey is NWQRXFSZRGOKBC-BGOANBRWSA-N. The full InChI is InChI=1S/C33H46N2O9S.2C33H46N2O7.C32H44N2O9S.C32H44N2O9.C31H43N3O7/c1-22(17-26(36)20-35-13-15-43-16-14-35)32(40)34-29(30(38)24-9-11-27(12-10-24)45(3,41)42)28(37)19-25(31(39)33(2)21-44-33)18-23-7-5-4-6-8-23;2*1-21(15-24(36)19-35-11-13-41-14-12-35)32(39)34-29(16-22-7-9-25(40-3)10-8-22)30(37)18-23(31(38)33(2)20-42-33)17-28-26-5-4-6-27(26)28;1-21(16-25(35)19-34-12-14-42-15-13-34)31(39)33-28(29(37)23-8-10-26(11-9-23)44(3,40)41)27(36)18-24(17-22-6-4-5-7-22)30(38)32(2)20-43-32;1-32(20-43-32)30(39)23(15-21-5-3-4-6-21)17-27(37)28(29(38)22-7-9-26(41-2)10-8-22)33-31(40)24(19-35)16-25(36)18-34-11-13-42-14-12-34;1-21(14-25(35)19-34-10-12-40-13-11-34)30(38)33-26(16-23-8-9-32-28(17-23)39-3)27(36)18-24(15-22-6-4-5-7-22)29(37)31(2)20-41-31/h7,9-12,22,25,29-30,38H,4-6,8,13-21H2,1-3H3,(H,34,40);2*7-10,21,23,26-29H,4-6,11-20H2,1-3H3,(H,34,39);6,8-11,21,24,28-29,37H,4-5,7,12-20H2,1-3H3,(H,33,39);5,7-10,23-24,28-29,35,38H,3-4,6,11-20H2,1-2H3,(H,33,40);6,8-9,17,21,24,26H,4-5,7,10-16,18-20H2,1-3H3,(H,33,38)/t22-,25-,29-,30-,33-;2*21-,23-,26-,27+,28?,29+,33-;21-,24-,28-,29-,32-;23-,24?,28-,29-,32-;21-,24-,26+,31-/m111111/s1.

What are the key properties of bis((2R)-N-[(2S,5R)-5-[[(1S,5R)-6-bicyclo[3.1.0]hexanyl]methyl]-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-methyl-5-morpholin-4-yl-4-oxopentanamide);(2R)-N-[(1R,2S,5R)-5-(cyclohexen-1-ylmethyl)-1-hydroxy-6-[(2R)-2-methyloxiran-2-yl]-1-(4-methylsulfonylphenyl)-3,6-dioxohexan-2-yl]-2-methyl-5-morpholin-4-yl-4-oxopentanamide;(2S)-N-[(1R,2S,5R)-5-(cyclopenten-1-ylmethyl)-1-hydroxy-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-(hydroxymethyl)-5-morpholin-4-yl-4-oxopentanamide;(2R)-N-[(1R,2S,5R)-5-(cyclopenten-1-ylmethyl)-1-hydroxy-6-[(2R)-2-methyloxiran-2-yl]-1-(4-methylsulfonylphenyl)-3,6-dioxohexan-2-yl]-2-methyl-5-morpholin-4-yl-4-oxopentanamide;(2R)-N-[(2S,5R)-5-(cyclopenten-1-ylmethyl)-1-(2-methoxy-4-pyridinyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-methyl-5-morpholin-4-yl-4-oxopentanamide?

bis((2R)-N-[(2S,5R)-5-[[(1S,5R)-6-bicyclo[3.1.0]hexanyl]methyl]-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-methyl-5-morpholin-4-yl-4-oxopentanamide);(2R)-N-[(1R,2S,5R)-5-(cyclohexen-1-ylmethyl)-1-hydroxy-6-[(2R)-2-methyloxiran-2-yl]-1-(4-methylsulfonylphenyl)-3,6-dioxohexan-2-yl]-2-methyl-5-morpholin-4-yl-4-oxopentanamide;(2S)-N-[(1R,2S,5R)-5-(cyclopenten-1-ylmethyl)-1-hydroxy-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-(hydroxymethyl)-5-morpholin-4-yl-4-oxopentanamide;(2R)-N-[(1R,2S,5R)-5-(cyclopenten-1-ylmethyl)-1-hydroxy-6-[(2R)-2-methyloxiran-2-yl]-1-(4-methylsulfonylphenyl)-3,6-dioxohexan-2-yl]-2-methyl-5-morpholin-4-yl-4-oxopentanamide;(2R)-N-[(2S,5R)-5-(cyclopenten-1-ylmethyl)-1-(2-methoxy-4-pyridinyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-methyl-5-morpholin-4-yl-4-oxopentanamide has a molecular weight of 3615.46 g/mol, XLogP of 14.39, 97 rotatable bonds, 10 hydrogen bond donors, and 55 hydrogen bond acceptors.

Where does this data come from?

All data for bis((2R)-N-[(2S,5R)-5-[[(1S,5R)-6-bicyclo[3.1.0]hexanyl]methyl]-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-methyl-5-morpholin-4-yl-4-oxopentanamide);(2R)-N-[(1R,2S,5R)-5-(cyclohexen-1-ylmethyl)-1-hydroxy-6-[(2R)-2-methyloxiran-2-yl]-1-(4-methylsulfonylphenyl)-3,6-dioxohexan-2-yl]-2-methyl-5-morpholin-4-yl-4-oxopentanamide;(2S)-N-[(1R,2S,5R)-5-(cyclopenten-1-ylmethyl)-1-hydroxy-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-(hydroxymethyl)-5-morpholin-4-yl-4-oxopentanamide;(2R)-N-[(1R,2S,5R)-5-(cyclopenten-1-ylmethyl)-1-hydroxy-6-[(2R)-2-methyloxiran-2-yl]-1-(4-methylsulfonylphenyl)-3,6-dioxohexan-2-yl]-2-methyl-5-morpholin-4-yl-4-oxopentanamide;(2R)-N-[(2S,5R)-5-(cyclopenten-1-ylmethyl)-1-(2-methoxy-4-pyridinyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-methyl-5-morpholin-4-yl-4-oxopentanamide is sourced from PubChem (CID 159906607), the world's largest open chemistry database maintained by the National Library of Medicine (NIH).